GeneDx Holdings Corp.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from GeneDx Holdings Corp.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 82% in 3 years; of every extra $100 of sales, $274 became extra profit. Higher than 89% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-5.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 54% of Healthcare companies in United States.
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $3 tied up three years earlier.
Less money tied up than 59% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$274Sales grew 82% in 3 years; of every extra $100 of sales, $274 became extra profit.
Higher than 89% of Healthcare companies in United States.
Asset Productivity Ratio
+82% / +7%In 3 years sales changed by +82% while total assets changed by +7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
7.3×Debt due within a year is covered 7.3 times by its yearly operating cash.
Higher than 83% of Healthcare companies in United States.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Lower than 62% of Healthcare companies in United States.
Tangible Assets Ratio
65%Of every $100 the company owns, $65 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 65% of Healthcare companies in United States.
Tangible Net Worth Ratio
41%Of every $100 of net worth, $41 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 58% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
GeneDx Holdings Corp. made a loss over the last year. GeneDx Holdings Corp. owes $0.49 for every $1 it owns. GeneDx Holdings Corp. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGeneDx Holdings Corp. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.20The share price is 8.20 times GeneDx Holdings Corp.'s book value per share, higher than 83% of Healthcare companies in United States.
Market cap
$2.0 BThe total market value of all of GeneDx Holdings Corp.'s shares at today's price (share price × number of shares), larger than 75% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$244 MWhat GeneDx Holdings Corp. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.19Net worth divided by the number of shares. The share price of $67.14 is 8.2 times this, which is the P/B above.
Return on equity (ROE)
-40.8%GeneDx Holdings Corp. lost 40.8% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
Owes vs Owns
0.49×GeneDx Holdings Corp. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Dividend yield
NoneGeneDx Holdings Corp. does not currently pay a dividend.
Revenue growth
+40%Revenue rose 40% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Profit growth
LossGeneDx Holdings Corp. made a loss in each of the last two years.
Profit margin
-4.9%GeneDx Holdings Corp. lost $5 for every $100 of revenue.
Cash vs debt
Net cashGeneDx Holdings Corp. held $58 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For GeneDx Holdings Corp.: $2.0 B ÷ $244 M (30 Jun 2026) = 8.2.
What is GeneDx Holdings Corp.'s return on equity?
GeneDx Holdings Corp. lost 40.8% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
How much does GeneDx Holdings Corp. owe compared with what it owns?
GeneDx Holdings Corp. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Does GeneDx Holdings Corp. pay a dividend?
No. GeneDx Holdings Corp. does not currently pay a dividend.
Is GeneDx Holdings Corp.'s revenue growing?
Revenue rose 40% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.